Chief Technological Officer (CTO) and member of the Scientific Advisory Board (SAB)

Eugene Zhukovsky is the Chief Technological Officer of BIOMUNEX and member of the SAB. He was the CSO of BIOMUNEX from 2015 to 2021. He has more than 25 years of international experience in biotherapeutics research and development and worked in biotech and pharma companies in the US, France, and Germany. His expertise is advancing novel antibody-based immunotherapeutics from discovery through to IND/IMPD submission. Eugene is the originating inventor of Monjuvi®, a recently approved Fc-optimized antibody for hematological malignancies. Well known in the field, Eugene was named as one of the top 50 Global Antibody Industry Influencers in 2013. Prior to joining BIOMUNEX as the CSO, he was the CSO of Affimed and held appointments at Boehringer Ingelheim, Xencor, Neurex, Lynx Therapeutics. Eugene holds a PhD in Biochemistry from Brandeis University (Waltham, MA, USA) and was a postdoctoral fellow at Genentech. In addition to authoring numerous articles in scientific journals, he is a co-inventor of more than 15 granted patents and patent applications, of which several are from BIOMUNEX.